https://www.selleckchem.com/products/mt-802.html
The median age was 12 years (IQR 8-15) and 55% were female. Two hundred and nine (68%) had viral load suppression (1,000 copies/ml) and 97(32%) were unsuppressed (viral load ≥100. At follow-up in 2018, 42/306 (14%) were either transferred 23 (7%) or LTFU 17 (6%) and 2 had died. In 2018, of the 264 retained in care, 107/264 (41%), had been switched to second-line, ritonavir-boosted PI with abacavir as a new nucleotide analog reverse transcriptase inhibitor (NRTI). Overall viral load suppression increased from 68% in 2016 to 81% in 2
Curtir
Comentario
Compartilhar
